Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques: Expressing, Staining, RNA Sequencing

Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: Association of shared gene signatures and progressed cell death involving apoptosis and ferroptosis. (A) Expression levels of apoptosis-related genes in cardiomyocytes under a hyperglycemic environment (GSE 62203). (B) Expression levels of apoptosis-related genes in diabetic tubules (GSE 30122). (C) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected apoptosis-related genes in cardiomyocytes under a hyperglycemic environment (GSE 62203). (D) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected apoptosis-related genes in diabetic tubules (GSE 30122). (E) Expression levels of ferroptosis-related genes in diabetic cardiomyocytes (GSE 62203) and kidneys (GSE 30122). (F) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected ferroptosis-related genes in diabetic cardiomyocytes (GSE 62203) and kidneys (GSE 30122). (G) Expression levels of ferroptosis-related genes in the peripheral blood of patients with type II diabetes (GSE 23561) and glomeruli of diabetic nephropathy (GSE 96804). (H) Correlation of the expression of two shared genes (PEA15 and TFPI2) and selected ferroptosis-related genes in the peripheral blood of patients with type II diabetes (GSE 23561) and glomeruli of diabetic nephropathy (GSE 96804). The data has been normalized, and batch effects have been handled. A T-statistic test was employed to compare the expression levels of shared genes between the two groups. ∗ P < 0.05, ∗∗ P < 0.01 and ∗∗∗ P < 0.01 denotes statistical significance. DCM: diabetic cardiomyopathy; DT: diabetic tubuli; DNT: diabetic nephropathy tubuli; DNG: diabetic nephropathy glomeruli; DM: diabetes mellitus

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques: Expressing

Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: Clinical significance of shared genes in the Nephroseq database is illustrated through the following associations. (A) the relationship between PEA15 expression and glomerular filtration rate across all measured samples. (B) The correlation between PEA15 expression and serum creatinine levels in living donors. (C) The association of TFPI2 expression with glomerular filtration rate across all measured samples, and (D) The relationship between TFPI2 expression and serum creatinine levels in samples from patients with diabetic nephropathy.

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques: Expressing, Filtration

Journal: Biochemistry and Biophysics Reports

Article Title: Transcriptome analysis of serum biomarker, shared gene signature and pharmacological targets between diabetic cardiomyopathy and nephropathy

doi: 10.1016/j.bbrep.2025.102194

Figure Lengend Snippet: Molecular docking of candidate compounds and shared genes, including transcription factor s. (A) Affinities of candidate compounds with RUNX2 (a transcription factor for PEA15), PEA15, and TFPI2. (B) Affinities of candidate compounds with transcription factors (HBA1, HBA2, and HBB) corresponding to the three hemoglobin subunits.

Article Snippet: PEA15 and TFPI2 expression in normal heart and kidney tissues is evidenced by the Human Protein Atlas. (A) Representative image: PEA15 and TFPI2 antibody staining in the kidney. (B) Representative image: PEA15 and TFPI2 expression in the kidney, measured using HPA RNA-seq. (C) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney, as measured by HPA RNA-seq. (D) Percentage of cell types expressing PEA15 and TFPI2 in the kidney, determined through HPA RNA-seq. (E) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the kidney cortex and medulla, measured using GTEx RNA-seq. (F) Representative image: PEA15 and TFPI2 antibody staining in cardiomyocytes. (G) Representative image: PEA15 and TFPI2 expression in heart muscle, measured with HPA RNA-seq. (H) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in heart muscle, as measured by HPA RNA-seq. (I) Percentage of cell types expressing PEA15 and TFPI2 in heart muscle, determined through HPA RNA-seq. (J) Average normalized transcripts per million (nTPM) of PEA15 and TFPI2 in the atrial appendage and left ventricle, measured using GTEx RNA-seq.

Techniques:

Journal: Journal of Cancer

Article Title: The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis

doi: 10.7150/jca.32886

Figure Lengend Snippet: Correlation of PEA15 expression with patient's clinical and pathological characteristics

Article Snippet: Rabbit polyclonal PEA15 antibody (1:200, Proteintech, USA), PEA-15 with phosphorylated Ser104 (PEA-15-pSer104), or PEA-15with phosphorylated Ser116 (PEA-15-pSer116)(Santa Cruz Biotechnology, Inc., Shanghai, China) were used.

Techniques: Expressing

Journal: Journal of Cancer

Article Title: The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis

doi: 10.7150/jca.32886

Figure Lengend Snippet: PEA15 expression in OC tissue samples and immunohistochemical staining of two phosphorylation sites S116 and S104 of PEA15in normal and tumor tissues. A-D: Representative images of PEA15 expression in OC are shown at 200x magnification. A: OC, scored as (-); B: OC, scored as (+); C: OC, scored as (++); D: OC, scored as (+++). E: Normal ovarian tissue with negative PEA15-Ser104 staining and tumor tissue with positive PEA15-Ser104 staining. F: Normal ovarian tissue with negative PEA15-Ser116 staining and tumor tissue with positive PEA15-Ser116 staining.

Article Snippet: Rabbit polyclonal PEA15 antibody (1:200, Proteintech, USA), PEA-15 with phosphorylated Ser104 (PEA-15-pSer104), or PEA-15with phosphorylated Ser116 (PEA-15-pSer116)(Santa Cruz Biotechnology, Inc., Shanghai, China) were used.

Techniques: Expressing, Immunohistochemical staining, Staining, Phospho-proteomics

Journal: Journal of Cancer

Article Title: The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis

doi: 10.7150/jca.32886

Figure Lengend Snippet: Kaplan-Meier analysis of overall survival in OC patients based on K-M plotter dataset. A: PEA15 expression is negatively correlated with overall survival (OS) and progression free survival (PFS) in OC patients; B-D: Correlation between PEA15 expression and overall survival is independent of clinical stage ( B ), type ( C ) and Grade ( D ). P -values were calculated by log-rank test.

Article Snippet: Rabbit polyclonal PEA15 antibody (1:200, Proteintech, USA), PEA-15 with phosphorylated Ser104 (PEA-15-pSer104), or PEA-15with phosphorylated Ser116 (PEA-15-pSer116)(Santa Cruz Biotechnology, Inc., Shanghai, China) were used.

Techniques: Expressing

Journal: Journal of Cancer

Article Title: The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis

doi: 10.7150/jca.32886

Figure Lengend Snippet: Silencing of PEA15 suppresses ovarian cancer cell proliferation in vitro and tumor growth in vivo . A: RT-PCR and western blotting experiments showing the PEA15 expression at mRNA and protein level in 5 OC cell lines. B: PEA15 knockdown efficiency was confirmed by RT-PCR in OVCAR8 and 3AO cells. C: The cell proliferation of Nc and sh-groups in OVCAR8 and 3AO cells were evaluated by CCK8 assay at 0, 24, 48, 72, 96h. The results showed that knockdown of PEA15 significantly inhibited the proliferation of OVCAR8 and 3AO cells in vitro (P<0.01). D: Plate colony formation assay of OVCAR8/PEA15-sh and 3AO/PEA15-sh and Nc cells on regular culture plates after 14 days of culture. Relative colony numbers of PEA15-sh cells were significantly lower than that of Nc cells. E: Photographs of tumors from mice inoculated with OVCAR8/Nc and OVCAR8/sh3 cells. F: Tumor weights of Nc and sh3 groups shown in figure F, n = 5

Article Snippet: Rabbit polyclonal PEA15 antibody (1:200, Proteintech, USA), PEA-15 with phosphorylated Ser104 (PEA-15-pSer104), or PEA-15with phosphorylated Ser116 (PEA-15-pSer116)(Santa Cruz Biotechnology, Inc., Shanghai, China) were used.

Techniques: In Vitro, In Vivo, Reverse Transcription Polymerase Chain Reaction, Western Blot, Expressing, Knockdown, CCK-8 Assay, Colony Assay

Journal: Journal of Cancer

Article Title: The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis

doi: 10.7150/jca.32886

Figure Lengend Snippet: Effect of PEA15 on cell apoptosis in OC cells. A-B: Downregulation of PEA15 significantly increased apoptosis in OVCAR8 and 3AO cells, the statistical results are shown on the left (* P < 0.05, ** P < 0.01). C-D: The expression of Bcl2, Bax and cleaved caspase3 were determined by RT-PCR and western blotting analysis in OVCAR8 and 3AO cells.

Article Snippet: Rabbit polyclonal PEA15 antibody (1:200, Proteintech, USA), PEA-15 with phosphorylated Ser104 (PEA-15-pSer104), or PEA-15with phosphorylated Ser116 (PEA-15-pSer116)(Santa Cruz Biotechnology, Inc., Shanghai, China) were used.

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot

Journal: Journal of Cancer

Article Title: The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis

doi: 10.7150/jca.32886

Figure Lengend Snippet: PEA15 is negatively regulated by miR212 and silencing of PEA15 abolishes the effects of miR212 in OC cell lines. A: A nalysis of TargetScan, miRwalk, picTar and miRBse datasets identified 3 miRNAs as potential target of PEA15. B-D: Effect of 3 miRNAs on the luciferase activity of WT PEA-15 3′UTR in OVCAR8 cells by luciferase reporter assay. Blank PEA-15 negative vector, Mock 3 miRNAs plus PEA-15 negative vector. Error bars mean ± SEM. E: The expression of miR212 is downregulated in ovarian tumor tissues compared with normal tissues. F: The expression of miR212 in 5 ovarian cancer cells. G: The protein expression of PEA-15 is down-regulated when miR-212 is overexpressed. H: Effect of reintroduction of PEA-15 on miR-212-induced cell proliferation by CCK-8 assay ( P < 0.01 with two-way ANOVA). I: Effect of reintroduction of PEA-15 on miR-212-induced cell apoptosis by Flow analysis ( P < 0.01 for both groups).

Article Snippet: Rabbit polyclonal PEA15 antibody (1:200, Proteintech, USA), PEA-15 with phosphorylated Ser104 (PEA-15-pSer104), or PEA-15with phosphorylated Ser116 (PEA-15-pSer116)(Santa Cruz Biotechnology, Inc., Shanghai, China) were used.

Techniques: Luciferase, Activity Assay, Reporter Assay, Plasmid Preparation, Expressing, CCK-8 Assay